However, a high percentage of ERα+ breast cancers are de-novo (15–20%) or acquired resistance (30–40%) to endocrine therapy progressing from hormone dependence to independence, although a functional ERα pathway is still maintained [4,6,7]. This evidence concerns the gene ESR1 and breast cancer.